Ian Mortimer has bought XENE on 2 days since Aug 2017

Ian Mortimer is the President and Chief Executive Officer of Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders, particularly epilepsy and rare CNS conditions. He has held this role since June 2021, after serving as President and Chief Financial Officer from March 2018, Corporate Secretary from June 2015 to March 2021, Chief Financial Officer and Chief Operating Officer from March 2015 to 2018, and Chief Financial Officer from October 2013 to 2015.(

Mortimer brings over 25 years of biotechnology experience, starting in laboratory research before transitioning to finance. Prior to Xenon, he was Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation (now Arbutus Biopharma) from 2007 to 2013, where he led its Nasdaq listing in 2010, and held various finance roles at Inex Pharmaceuticals from 1997 to 2007, becoming CFO in 2004. He holds a Bachelor of Science in Microbiology from the University of British Columbia and a Master of Business Administration from Queen's University. Mortimer serves on the BIOTECanada Board of Directors since 2023 and was a 2023 Bloom Burton Award finalist. Recently, on December 5 and 8, 2025, he sold 25,205 shares under a Rule 10b5-1 plan for $1.14 million, retaining 8,010 shares directly.(

Written by Perplexity from public sources.